Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Interest & Investment Income (2017 - 2026)

United Therapeutics' Interest & Investment Income history spans 15 years, with the latest figure at $43.2 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 12.37% to $43.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $192.0 million, a 3.57% decrease, with the full-year FY2025 number at $192.0 million, down 3.57% from a year prior.
  • Interest & Investment Income hit $43.2 million in Q4 2025 for United Therapeutics, down from $46.4 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for UTHR hit a ceiling of $53.8 million in Q1 2024 and a floor of $3.8 million in Q3 2021.
  • Historically, Interest & Investment Income has averaged $30.8 million across 5 years, with a median of $40.2 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: crashed 53.0% in 2021 and later surged 579.07% in 2023.
  • Tracing UTHR's Interest & Investment Income over 5 years: stood at $4.2 million in 2021, then skyrocketed by 395.24% to $20.8 million in 2022, then soared by 145.19% to $51.0 million in 2023, then decreased by 3.33% to $49.3 million in 2024, then fell by 12.37% to $43.2 million in 2025.
  • Business Quant data shows Interest & Investment Income for UTHR at $43.2 million in Q4 2025, $46.4 million in Q3 2025, and $51.3 million in Q2 2025.